AtriCure, Inc. ATRC
At closeNov 4, 2026, 4:21 PM EST
After hours · Nov 4, 4:21 PM ET
- YTD
- +65.65%
- 1 year
- +100.09%
- Market cap
- 3.33B
- Revenue (ttm)
- 569.62M
- Profit margin
- 1.85%
- EPS (ttm)
- 0.21
- Shares out
- 50.87M
- P/E ratio
- 312.05
- Forward P/E
- 154.03
- YTD return
- +65.65%
- 1-year return
- +100.09%
- Volume
- 1.34M
- Avg volume
- 1.02M
- Open
- 58.06
- Previous close
- 60.41
- Day's range
- 58.00 – 66.02
- 52-week range
- 25.36 – 66.02
- Beta
- 1.21
- Analysts
- Buy
- Price target
- 57.56 (-12.2%)
- Earnings date
- Feb 16, 2027
YTD +26.23 (+66.79%)
Key statistics
- Enterprise value
- 2.98B
- PEG ratio
- 10.00
- Price / sales
- 5.85
- Price / book
- 6.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 12.80%
- Free cash flow
- 48.81M
- Total cash
- 167.79M
- Total debt
- 74.22M
- Return on equity
- 2.15%
- Short % of float
- 10.00%
- 50-day average
- 56.03
- 200-day average
- 38.28
Analyst view
Consensus: buy
- Target (low)
- 36.00
- Target (mean)
- 57.56
- Target (high)
- 68.00
- Strong buy3
- Buy4
- Hold3
- Sell0
- Strong sell0
Next earnings
Feb 16, 2027
Expected Feb 16, 2027. Consensus EPS estimate 0.08184.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 16, 2027 | Dec 30, 2026 | 0.00717 | — | — | — |
| Nov 3, 2026 | Sep 30, 2026 | -0.0552 | 0.17 | +0.23 | +407.97% |
| Jul 23, 2026 | Jun 30, 2026 | -0.00167 | 0.18 | +0.18 | +10,878.44% |
| May 5, 2026 | Mar 31, 2026 | -0.07 | 0.0022 | +0.07 | +103.14% |
| Feb 17, 2026 | Dec 31, 2025 | -0.04003 | 0.06 | +0.10 | +249.89% |
| Oct 29, 2025 | Sep 30, 2025 | -0.11 | -0.01 | +0.10 | +90.91% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 4, 2026 | JP Morgan | main | Neutral | Neutral |
| Nov 4, 2026 | Piper Sandler | reit | Overweight | Overweight |
| Nov 4, 2026 | Needham | main | Buy | Buy |
| Nov 4, 2026 | BTIG | main | Buy | Buy |
| Oct 21, 2026 | Citizens | main | Market Outperform | Market Outperform |
| Oct 12, 2026 | BTIG | main | Buy | Buy |
About AtriCure, Inc.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- atricure.com
News
Piper Sandler Reiterates Overweight on AtriCure, Raises Price Target to $70
Block To Rally Around 54%? Here Are 10 Top Analyst Forecasts For Wednesday
AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results Needham Maintains Buy on AtriCure, Raises Price Target to $70
BTIG Maintains Buy on AtriCure, Raises Price Target to $70
AtriCure, Inc. (ATRC) Q3 2026 Earnings Call Transcript
What AtriCure (ATRC) Said on Its Q3 Earnings Call
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
Your note
Sign in to keep a note on ATRC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARREL MICHAEL H | Chief Executive Officer | Stock Gift | Jul 29, 2026 | 792,694 |
| DAHLQUIST KARL S | Officer | Sale | Aug 23, 2026 | 87,319 |
| DORAISWAMY VINAYAK | Officer | Sale | Jul 27, 2026 | 86,511 |
| JOHNSON B KRISTINE | Director | Stock Award(Grant) | May 17, 2026 | 55,954 |
| NOZNESKY JUSTIN J | Officer | Sale | Jul 28, 2026 | 100,219 |
| PRIVITERA SALVATORE | Chief Technology Officer | Sale | Sep 22, 2026 | 142,745 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.80% | 4,474,548 | 293.22M | Jun 29, 2026 |
| Wellington Management Group, LLP | 6.87% | 3,495,603 | 229.07M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 6.15% | 3,127,195 | 204.93M | Jun 29, 2026 |
| Hood River Capital Management LLC | 5.71% | 2,905,299 | 190.38M | Jun 29, 2026 |
| Alliancebernstein L.P. | 5.44% | 2,768,365 | 181.41M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.31% | 2,190,413 | 143.54M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.95% | 3,028,653 | 198.47M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 3.00% | 1,527,073 | 100.07M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 1,519,312 | 99.56M | Jun 29, 2026 |
| Delaware Group Equity Funds V-Nomura Small Cap Core Fund | 2.71% | 1,377,902 | 90.29M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.54% | 1,291,358 | 84.62M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.17% | 1,102,113 | 72.22M | Jun 29, 2026 |
